Pharmaceuticals
Hims & Hers falls 8% after Novo’s legal threat. Here’s the latest
Rafael Henrique | SOPA Images | AP The stock of Hims & Hers dropped in premarket trading early Friday after a legal threat from Novo Nordisk. The online teleheath company announced on Thursday plans to launch a cheaper, copycat version of Novo’s weight loss pill, prompting Novo to take legal action. Hims stock spiked as […]
Read More
The White House is launching direct-to-consumer drug site Trump Rx. Here’s what to know
U.S. President Donald Trump makes an announcement from the Oval Office at the White House in Washington, D.C., U.S. Nov. 6, 2025. Jonathan Ernst | Reuters President Donald Trump on Thursday is slated to announce the launch of TrumpRx – a direct-to-consumer website that is key to his administration’s efforts to lower prescription drug costs […]
Read More
Novo Nordisk and Eli Lilly tumble after Hims & Hers announce $49 copy of Wegovy pill
Weight-loss drugmakers Eli Lilly and Novo Nordisk tumbled after telehealth company Hims & Hers announced Thursday it will offer a copy of the newly launched Wegovy pill for $49, far less than the $149 Novo sells the branded pill for. Copenhagen-listed shares of Novo dropped as much as 9% on the news, while Eli Lilly […]
Read More
Eli Lilly’s GLP-1 growth is only getting started as Novo Nordisk braces for a decline in 2026
The Eli Lilly and Novo Nordisk logos. Mike Blake | Tom Little | Reuters It’s a tale of two drugmakers in the red-hot obesity drug market. Both Novo Nordisk and Eli Lilly are grappling with lower prices in the U.S., but their 2026 outlooks are diverging sharply: While Novo is bracing for a sales decline, […]
Read More
Eli Lilly blows past quarterly estimates, posts strong outlook as Zepbound and Mounjaro sales soar
Eli Lilly and Company’s logo is displayed during a press conference in Houston, Texas, U.S., Sept. 23, 2025. Antranik Tavitian | Reuters Eli Lilly on Wednesday posted fourth-quarter earnings and revenue and 2026 guidance that blew past estimates, as demand for its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro soars. The pharmaceutical giant […]
Read More
Novo Nordisk shares tumble after company forecasts sales declines this year
Novo Nordisk‘s U.S. shares plummeted Tuesday after the company said it sees sales and profit growth declining this year, hit by lower prices in the U.S. and loss of exclusivity for its blockbuster Wegovy and Ozempic in China, Brazil and Canada. The company published the forecast as it reported full-year 2025 sales, ahead of the […]
Read More
Merck tops quarterly estimates, posts modest 2026 guidance as generic competition looms
Merck on Tuesday reported fourth-quarter earnings and revenue that topped estimates on strong demand for its cancer immunotherapy Keytruda and some newer products. But the company posted a modest 2026 outlook that fell short of Wall Street’s expectations as it prepares for a few drugs to lose patent protection later this year and face generic […]
Read More
Pfizer says obesity injection shows promise as monthly treatment in mid-stage trial
Smith Collection | Archive Photos | Getty Images Pfizer on Thursday said its experimental obesity drug, which it acquired through Metsera, drove solid weight loss when taken once a month in a mid-stage trial. Patients with obesity or who are overweight lost up to 12.3% of their weight compared with placebo at week 28 in […]
Read More
Pfizer beats quarterly estimates despite Covid product decline, reaffirms modest outlook
Albert Bourla, CEO of Pfizer, speaking on Squawk on the Street at the World Economic Forum in Davos, Switzerland on Jan. 20, 2026. Oscar Molina | CNBC Pfizer on Tuesday reported fourth-quarter results that topped estimates even amid dwindling demand for its Covid products, while reaffirming its modest 2026 guidance that rattled investors in December. […]
Read More
AstraZeneca is listing in New York, as Big Pharma balances the huge U.S. market with China’s tempting innovation
Pharma giant AstraZeneca will list on the New York Stock Exchange on Monday, days after it announced big commitments on the other side of the world. Like the rest of Big Pharma, the company has a balancing act. It wants a close relationship with the U.S., its biggest market, and the listing is intended to […]
Read More